Cresco Labs Stock Price, News & Analysis

Cresco Labs (OTCQX:CRLBF), a leading branded cannabis products company and operator of Sunnyside dispensaries, has scheduled its Second Quarter 2025 earnings release for August 7, 2025, before market opening.

The company will host a conference call and webcast at 8:30 am ET to discuss financial results and business highlights. Investors can access the call through US toll-free (1-833-470-1428) or US local (1-404-975-4839) numbers using access code 158138. The webcast recording will be available for one year on Cresco's investor relations website.

Cresco Labs announced a change in its independent auditor from Marcum LLP to Baker Tilly US, LLP, effective June 12, 2025. The transition follows a comprehensive three-month selection process and received approval from both the audit committee and board of directors. Baker Tilly will commence its engagement with the review of Cresco's Q2 2025 financial statements. CFO Sharon Schuler expressed confidence in Baker Tilly's expertise and their future collaboration. Notably, there were no modified opinions in Marcum's previous audit reports, and no reportable events were identified during their tenure. The change of auditor documentation has been filed on SEDAR+ in accordance with regulatory requirements.

Cresco Labs (CRLBF) reported solid Q1 2025 financial results, highlighted by $166 million in revenue and strong cash generation. The company achieved $30 million in operating cash flow and $25 million in Free Cash Flow, ending the quarter with $162 million in cash - its highest balance in three years. Financial metrics include $79 million in gross profit, adjusted gross margin of 49%, and Adjusted EBITDA of $36 million (22% margin). Despite posting a net loss of $15 million, the company maintained its #1 market share position in multiple billion-dollar markets. Management emphasized their focus on balance sheet strength, strategic capital deployment, and reduced credit risk in wholesale accounts.

Cresco Labs (CRLBF) has announced an updated schedule for its first quarter 2025 earnings release. The company will file its Q1 interim financial statements and MD&A on Friday, May 30, 2025. Following a three-week review period with independent auditors, Cresco confirmed no material changes were found from the preparation made for May 9th.

The earnings conference call and webcast is scheduled for Monday, June 2, 2025, at 8:30 am ET. The webcast recording will be accessible for one year through Cresco Labs' investor relations website.

Cresco Labs (CRLBF) has announced the grand opening of a new Sunnyside dispensary in Chippewa Township, Beaver Falls, Pennsylvania. The dispensary, located at 2634 Darlington Road, is strategically positioned just 1.5 miles northwest of I-376, making it easily accessible to patients from nearby towns including New Brighton, West Mayfield, and New Beaver.

According to CEO Charlie Bachtell, Pennsylvania remains a standout market for Cresco Labs, where the company holds the #1 position in branded market share. The new location demonstrates Cresco's strategy of deepening its presence in core states while leveraging its strong retail presence. The dispensary will operate Sunday through Thursday from 9 a.m. to 6 p.m., and Friday and Saturday from 9 a.m. to 7 p.m.

Cresco Labs (CRLBF) has announced the postponement of its Q1 2025 earnings call, originally scheduled for May 9, 2025. The company needs additional time to complete the review procedures for its first quarter interim financial statements. The cannabis company expects to host the rescheduled earnings call and file its Q1 interim financial statements by the required filing deadline of May 30, 2025. A new earnings call date will be announced once determined.

Cresco Labs, a leading cannabis products company and operator of Sunnyside dispensaries, has scheduled its first quarter 2025 financial results announcement for May 9, 2025, before market opening.

The company will host a conference call and webcast at 8:30 am ET to discuss Q1 2025 performance and highlight key business developments. Investors can participate through multiple channels:

• US Toll-Free: 1-833-470-1428
• US Local: 1-404-975-4839
• Access Code: 671160

The webcast recording will remain accessible for one year through Cresco Labs' investor relations website. The company, which trades on multiple exchanges (CSE:CL, OTCQX:CRLBF, FSE:6CQ), maintains its position as an industry leader in branded cannabis products across America.

Cresco Labs reported strong financial results for 2024, achieving record operating cash flow of $132 million, up 126% year-over-year. The company generated annual revenue of $724 million with an Adjusted EBITDA of $200 million, increasing 15% from the previous year.

Key financial highlights include gross profit of $364 million, adjusted gross margin of 52% (improving 270 bps), and reduced Adjusted SG&A by 12% to $212 million. The company reported a net loss of $60 million, including one-time non-cash charges of $66 million related to 280E position benefits.

Cresco maintained market leadership as the No. 1 share position in Illinois, Pennsylvania, and Massachusetts throughout 2024. The company ended the year with $141 million in cash and announced expansion into Kentucky as one of only two Tier 3 cultivators, with up to 25,000 square feet of canopy representing over 20% of the state's total allocation.

Cresco Labs has secured a management services agreement for a Tier 3 Cultivation License in Kentucky, becoming one of only two operators with this coveted license type. The agreement allows Cresco to manage and operate a cultivation facility with up to 25,000 square feet of canopy.

Kentucky's medical cannabis program, which launched on January 1, 2025, includes a total of 115,000 square feet of approved canopy space and 48 retail licenses. Industry analysts project the market to generate over $135 million in revenue by 2026, expanding to more than $228 million by 2028.

CEO Charlie Bachtell emphasized that this expansion represents the company's first opportunity to reinvest free cash flow into high ROIC growth initiatives, following two years of core business solidification.